Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Enspryng (satralizumab) for Thyroid eye disease (TED)

FDA decision
Oct 152026
Approved
October has 3 FDA decisions on our calendar, this one included. Before it, Camzyos on Sep 30th. After it, Ultomiris on Oct 21st.
Approved
The FDA approved this application. Approval is the starting line, not the finish: our guide to what happens in the 90 days after a rare disease approval walks through specialty pharmacies, insurance review, and how families shorten the wait.

What the FDA decided on Enspryng for Thyroid eye disease

The FDA approved Enspryng (satralizumab) for thyroid eye disease (TED).

Approved for adults with thyroid eye disease whether the disease is active or chronic, approved by the FDA on October 15, 2026, its target date, and announced by Genentech and Roche the next day. It is the first treatment for the disease that people can inject at home, and the first that blocks the interleukin-6 receptor rather than IGF-1R, the target of Tepezza and Lumvoa.

The dose is 120mg, or 180mg for people over 100kg, at weeks 0, 2 and 4 and then every 4 weeks. The approval rests on 2 Phase 3 trials: in SatraGO-2, 52.9% of people with active disease had their eye bulging improve by at least 2mm at week 24 against 23.4% on placebo, while SatraGO-1 missed its primary endpoint at 49.0% against 31.2%.

The label has no hearing warning; its warnings cover infections, raised liver enzymes, low neutrophil counts and allergic reactions. Enspryng is also under FDA review for MOGAD, with a decision due January 10, 2027.

Who the Enspryng decision matters to

Thyroid eye disease (TED) is a rare autoimmune condition in which the immune system attacks the muscles and fat behind the eyes, causing bulging eyes, double vision, pain, and in severe cases vision loss. It most often occurs alongside Graves' disease.

Three drugs are now FDA approved: 2 IGF-1R infusions and, since October 2026, an IL-6 receptor blocker people inject at home, with pills and other injections in late-stage trials.

Prevalence: About 16 in 100,000 women and 3 in 100,000 men diagnosed each year; up to half of people with Graves' disease develop some degree of TED. See our full Thyroid Eye Disease page for current treatments, recruiting trials, and community resources.

How Enspryng works

Enspryng: humanized recycling antibody against the interleukin-6 receptor, binding both the soluble and membrane-bound forms to block IL-6 signaling. Our full Enspryng profile covers how it works, side effects in plain language, and its trial history.

Where Thyroid Eye Disease treatment stands today

FDA approved for Thyroid Eye Disease (3)
Tepezza (teprotumumab)IGF-1R inhibitor monoclonal antibodysince 2020Enspryng (satralizumab)IL-6 receptor antagonistsince 2026Lumvoa (veligrotug)IGF-1R inhibitor monoclonal antibodysince 2026
Read our full Thyroid Eye Disease treatment summary

Three drugs are FDA approved for TED. Two target IGF-1R, the receptor driving tissue expansion behind the eyes. Teprotumumab (Tepezza, approved January 2020) is given as 8 infusions over about 5 months.

Veligrotug (Lumvoa, approved June 2026) is given as 5 infusions over 12 weeks and is the first therapy with label data covering both active and chronic TED.

The third, Enspryng (satralizumab), was approved in October 2026 for adults with TED whether active or chronic. It blocks the IL-6 receptor instead, is injected under the skin at home every 4 weeks after 3 starting doses, met its primary endpoint in 1 of its 2 Phase 3 trials (SatraGO-2, 52.9% proptosis responders versus 23.4% on placebo) and carries no hearing warning.

The pipeline is aimed at making treatment easier to take: elegrobart, an injection under the skin, met its main goal in Phase 3 trials in both active TED (REVEAL-1, March 2026) and chronic TED (REVEAL-2, May 2026), and Viridian plans to apply to the FDA in the first quarter of 2027. An oral pill, linsitinib, is in a recruiting Phase 3 trial (NCT07753603).

Another injectable antibody, lonigutamab, has no active trial listed on ClinicalTrials.gov, and its owner, Alumis, said in May 2026 that it would explore strategic alternatives for the program.

IGF-1R blockers can affect hearing, so trials and treatment alike include hearing checks; mention any hearing changes to your care team promptly. An oculoplastic specialist or a neuro-ophthalmologist experienced in TED is the right doctor to ask about trial eligibility, which often depends on whether your disease is active or chronic.

The Thyroid Eye Disease page has every treatment and trial →

Meanwhile, 51 Thyroid Eye Disease studies are recruiting or not yet recruiting

The FDA's decision does not end research on Thyroid Eye Disease. The most recently updated:

Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
Treatment trial · NCT07885605 · has US sites
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Treatment trial · NCT07753603 · has US sites
Treatment of Chronic Thyroid Eye Disease With MHB018A
Treatment trial · NCT07622121 · has US sites
See all 51 open studies →
Get the next Thyroid Eye Disease update by email

You'll hear about future FDA decisions and new recruiting trials for Thyroid Eye Disease. Unsubscribe anytime.

You'll get, for Thyroid Eye Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Or get every FDA decision, for any condition

One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.

We never share your email. Stop anytime from the link in every email. Privacy policy

Frequently asked questions

Has the FDA decided on Enspryng?

The FDA has already decided. It approved the application.

Details: the outcome and what it means are at the top of this page.

Source: Roche press release

What was Enspryng approved for?

The FDA approved Genentech (Roche)'s sBLA for Enspryng in Thyroid eye disease (TED).

What to know: Approved for adults with thyroid eye disease whether the disease is active or chronic, approved by the FDA on October 15, 2026, its target date, and announced by Genentech and Roche the next day. It is the first treatment for the disease that people can inject at home, and the first that blocks the interleukin-6 receptor rather than IGF-1R, the target of Tepezza and Lumvoa. The dose is 120mg, or 180mg for people over 100kg, at weeks 0, 2 and 4 and then every 4 weeks. The approval rests on 2 Phase 3 trials: in SatraGO-2, 52.9% of people with active disease had their eye bulging improve by at least 2mm at week 24 against 23.4% on placebo, while SatraGO-1 missed its primary endpoint at 49.0% against 31.2%. The label has no hearing warning; its warnings cover infections, raised liver enzymes, low neutrophil counts and allergic reactions. Enspryng is also under FDA review for MOGAD, with a decision due January 10, 2027.

How it works: Humanized recycling antibody against the interleukin-6 receptor, binding both the soluble and membrane-bound forms to block IL-6 signaling.

More: the Enspryng drug page explains it in plain language.

Is there already an FDA-approved treatment for Thyroid Eye Disease?

Yes. Trial Friend's drug list includes 3 FDA-approved drugs for Thyroid Eye Disease.

Approved: Tepezza (teprotumumab), Enspryng (satralizumab), Lumvoa (veligrotug).

Check: the Thyroid Eye Disease page also searches FDA drug labels for approved treatments.

What did the Enspryng trials show?

For thyroid eye disease, the identically designed Phase 3 trials SatraGO-1 (NCT05987423, 131 patients) and SatraGO-2 (NCT06106828, 127 patients) measured the share of active-disease patients whose eye bulging improved by at least 2mm at week 24. SatraGO-2 met its primary endpoint, 52.9% versus 23.4% on placebo (p = 0.0011), while SatraGO-1 did not, 49.0% versus 31.2% (p = 0.0715).

More: the Enspryng drug page has the full trial history and sources.

What are the side effects of Enspryng?

The label carries no boxed warning. Its warnings are the ones shared by IL-6 receptor blockers: an increased risk of infections including serious and potentially fatal ones, raised liver enzymes, lowered neutrophil counts and hypersensitivity reactions.

Most common: Nasopharyngitis, Headache, Upper respiratory infection, Gastritis, Rash, Joint and limb pain.

More: the Enspryng drug page has the label's warnings in full.

How much will Enspryng cost?

Trial Friend does not list a price for Enspryng. What you pay depends on your insurance and on help from the drugmaker or a charity fund.

Drugmaker help: Genentech Access Solutions for Enspryng.

Find help: the patient assistance finder lists programs by insurance type.

What happens after the Enspryng decision?

The FDA approved Enspryng for Thyroid eye disease (TED) on October 15, 2026.

Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.

Where this outcome comes from

The outcome on this page comes from Roche press release. This page rechecks against our calendar, which is re-verified daily.